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Abstract 
Isavuconazole is a broad-spectrum triazole antifungal drug recently approved for the therapy of 
both invasive aspergillosis and mucormycosis. To support a widespread therapeutic drug 
monitoring (TDM) of isavuconazole, a simple, sensitive, and precise high-performance liquid 
chromatography (HPLC) method with UV detection was developed and fully validated for the 
quantification of this drug in human plasma. The method involved a combined protein 
precipitation-solid-phase extraction and a chromatographic separation on a Waters XTerra RP18 
(150 mm × 4.6 mm, 3.5 µm) column using an isocratic mobile phase of ammonium acetate buffer 
(pH 8.0, 10 mM) and acetonitrile (45:55, v/v). The UV detection was performed at 285 nm. This 
method was linear (correlation coefficients ³ 0.998), specific (no interference with plasma 
components or various potentially co-administrated drugs), sensitive (lower limit of quantification 
of 0.025 µg/mL), reproducible (coefficients of variation were £ 7.9%), and accurate (deviations 
ranged from -5.0% to 8.0%) over the range of 0.025–10 µg/mL. The method fulfilled all the FDA 
guidelines validation criteria and performed well in an international proficiency testing program. 
The assay was also successfully applied to a routine TDM of patients and to drug stability 
investigations under various conditions.   
 
Keywords: isavuconazole, triazole drug, solid-phase extraction, HPLC-UV, therapeutic drug 
monitoring. 
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1.  INTRODUCTION 
Isavuconazole (ISC, formerly termed BAL4815) is a new triazole antifungal drug recently licensed 
(in 2015) for the treatment of invasive aspergillosis and mucormycosis (Astellas Pharma US, 
2015).  ISC acts on a wide range of clinically relevant yeasts, molds, and dimorphic fungi by 
blocking the synthesis of ergosterol and leading to the production of aberrant and potentially toxic 
sterols on the fungal cell membrane (Guinea et al., 2008; Miceli and Kauffman, 2015). 
ISC is administered as a prodrug (isavuconazonium sulphate, also known as BAL8557) 
available in an intravenous formulation and also as oral capsules, since its has high oral 
bioavailability (nearly 100%).  The water-soluble prodrug is rapidly hydrolyzed by plasma 
esterases and almost completely converted to ISC (~98%) (Miceli and Kauffman, 2015; Schmitt-
Hoffmann et al., 2006a; Schmitt-Hoffmann et al., 2006b).  The recommended dosing regimen of 
ISC in both oral and IV formulations is 200 mg every 8 hours for 2 days as a loading dose 
followed by a maintenance dose of 200 mg once daily (Astellas Pharma US, 2015).   
Although ISC has a better tolerability and fewer CYP-mediated drug interactions than other 
triazole drugs, therapeutic drug monitoring (TDM) of ISC is required, especially in certain clinical 
cases, to optimize clinical outcome in terms of improving efficacy and reducing drug-related 
adverse effects (Stott and Hope, 2017; Bellmann and Smuszkiewicz, 2017).  As highlighted at the 
6th European Conference on Infections in Leukaemia (ECIL), TDM of ISC is indicated in 
unresponsive infections, in the treatment of pathogens with reduced susceptibility, or in the case of 
drug-drug interactions (Lewis et al., 2015).  In fact, since ISC is a moderate CYP3A4 inhibitor, 
some drug-drug interactions were already observed (Bellmann and Smuszkiewicz, 2017).  For 
example, an increase of ISC levels has to be considered under treatment with lopinavir and 
ritonavir, while concomitant therapy with rifampin, carbamazepine, barbiturates or St John’s wort 
is contra-indicated because of resulting sub-therapeutic ISC levels (Bellmann and Smuszkiewicz, 
2017).  TDM of ISC is also recommended in subjects with severe hepatic impairment, as little is 
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known about the drug pharmacokinetics properties in this group of patients (European Medicines 
Agency, 2015; Desai et al., 2016).  
Some analytical methods have been reported so far for the determination of ISC in human 
plasma and most of them employed mass spectrometry or fluorescence detection (Schmitt-
Hoffmann et al., 2006a; Schmitt-Hoffmann et al., 2006b; Farowski et al., 2010; Toussaint et al., 
2017; Jørgensen et al., 2017; Müller et al., 2017; Fatiguso et al., 2017; McShane and Wang 2017).  
Alternatively, a method based on ultra-performance liquid chromatography (UPLC) coupled with 
UV detection has also been developed (Verweij-van Wissen et al., 2012).  However, this method 
requires specialized equipment that is not available in all clinical laboratories.  To promote 
widespread TDM of ISC, alternative methods which employ standard equipment and are simpler 
and easier to set up, would be desirable.  To the best of our knowledge, no validated high-
performance liquid chromatography (HPLC)-UV method has been yet developed to measure ISC 
concentrations in human plasma. 
Thus, the aim of this work was to develop a widely applicable, very simple and still robust 
HPLC-UV method, eligible for a clinical routine use.  This paper describes the development and 
validation of the first HPLC-UV method for the quantification of ISC in human plasma, which 
employs a rapid precipitation of plasma proteins with acetonitrile followed by a solid-phase 
extraction (SPE) procedure and an isocratic elution.  This assay is highly precise, accurate, 
selective, sensitive and suitable for a routine TDM of ISC in a clinical laboratory with standard 
equipment.  Moreover, this study reports the stability of ISC under several common conditions 
which can occur during the sample handling and analysis in the whole TDM process, including 
thermal inactivation of pathogenic microorganisms and exposure to ambient light. 
 
2.  EXPERIMENTAL 
2.1  Chemicals and reagents 
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ISC powder was kindly provided by Basilea Pharmaceutica Ltd. (Basel, Switzerland) and its 
chemical purity was above 99%.  Acetonitrile (HPLC Gradient Grade, LiChrosolv) was obtained 
from Merck (Darmstadt, Germany), methanol for chromatography was from Carlo Erba (Milan, 
Italy).  All other chemicals were of analytical or HPLC grade and purchased from J. T. Baker 
(Deventer, The Netherlands).  Ultrapure water used in all experiments was supplied by a Milli-Q 
water purification system (Millipore, Bedford, MA, USA).  SPE cartridges (Oasis HLB 1cc) were 
obtained from Waters (Milford, MA, USA).  Blank human plasma used for the preparation of 
quality controls (QCs) and calibrators was obtained from Seracare Life Sciences (Basematrix 53, 
Defibrinated human plasma, Milford, MA).   
 
2.2  Equipment and chromatographic conditions 
The HPLC system consisted of an Alliance 2695 Separation Module and a Photodiode Array 
Detector (PDA, 2996) connected to the Empower data acquisition software (version 2.0) (Waters, 
Milford, MA, USA).  Chromatographic separation was carried out on an XTerra RP18 (150 mm × 
4.6 mm, particle size 3.5 μm; Waters) analytical reversed-phase column equipped with an XTerra 
RP18 (20 mm × 3.9 mm, particle size 5 μm; Waters) guard column, both thermostated at 40°C.  
Samples were separated using an isocratic mobile phase consisting of acetonitrile - ammonium 
acetate buffer (pH 8.0, 10 mM) (55:45, v/v), previously filtered through a 0.22 μm membrane filter 
(Millipore, Bedford, MA, USA).  The flow rate was 1.0 mL/min and the total assay run time was 
12 min.  UV detection was set at 285 nm.  An Extraction Manifold (Waters) liquid handling 
system was used to perform the sample preparation.  A DRI-BLOCK DB-3 evaporator (Techne, 
Stone, United Kingdom) was used for drying eluates from SPE. 
 
2.3  Stock solutions, working solutions, calibration standards and quality control (QC) 
samples preparation 
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Stock solutions of ISC, at the concentration of 1 mg/mL, were prepared in methanol. Working 
solutions, at the concentration of 500, 200, 100, 50, 20, 10, 5, and 2.5 µg/mL, were then obtained 
through scalar dilutions from the ISC stock solution in methanol.  Both the stock and working 
solutions were stored at –20°C.  Plasma calibration standards at 10, 5, 2, 1, 0.5, 0.2, 0.1, 0.05, and 
0.025 µg/mL were freshly prepared by 1:100 dilution of the respective stock or working solution 
in human plasma and analyzed on the same day.  Of note, the total added volume of organic 
solvent spiked in all samples corresponded to 1% of the biological sample, a value below the 
threshold level of 2% recommended for non-biological matrix by the FDA guidelines (US Food 
and Drug Administration, 2013). Quality control (QC) samples at low (0.1 µg/mL), medium (1 
µg/mL), high (7.5 µg/mL) concentration levels as well as the lower and the upper limit of 
quantification (LLOQ = 0.025 µg/mL and ULOQ = 10 µg/mL, respectively) were prepared by 
diluting the working solutions in plasma.  The QC samples were prepared in batches at the same 
occasion, stored at –20°C, and then thawed and thermized at 60°C for 60 min on the day of 
analysis. 
 
2.4  Sample preparation  
Blood samples (5 mL) were withdrawn from patients and collected in tubes with K3EDTA as an 
anticoagulant.  Plasma samples were obtained after centrifugation of blood samples at 1,600 x g 
for 10 min at 4°C (Sigma Centrifuge, Model 2K15) and then stored at –80°C until analysis.  On 
the day of analysis, plasma samples were thawed and heated at 60°C for 60 min.  Three hundred 
and fifty µL of heat-inactivated plasma samples were deproteinized by addition of 350 µL of 
acetonitrile, vortexed thoroughly, and then centrifuged at 15,000 x g for 5 min at room temperature 
(RT).  An aliquot of 500 µL of supernatants was transferred to clean tubes and diluted 1:1 with 
500 µL of Milli-Q water.  Samples clean-up was then achieved using Oasis HLB 1cc cartridges 
(Waters) following the SPE procedure suggested by the manufacturer’s instructions, with minor 
modifications.  Briefly, the sample mixtures were loaded into Oasis HLB 1cc cartridges, already 
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activated and equilibrated with 1 mL of methanol and 1 mL of water, respectively.  After a 
washing step with 1 mL of 5% methanol diluted in water (v/v), the analyte was eluted from the 
cartridges with 0.5 mL of 100% methanol, collected and finally evaporated to dryness under a N2 
stream at 40°C.  The dried residues were then reconstituted with 62.5 µL of mobile phase and 
centrifuged at 15,000 x g for 5 min at RT.  The supernatants were transferred to HPLC vials and 
kept at 4°C in the autosampler until analysis.  The injection volume for each sample was 20 µL.   
 
2.5  Method validation 
This method was validated to meet the acceptance criteria of the FDA guidelines for bioanalytical 
method validation (US Food and Drug Administration, 2013).  Assay validation was performed to 
assess the recovery, limit of detection (LOD) and LLOQ, selectivity, specificity, linearity, 
accuracy, and precision of the method.   
 
2.5.1 Extraction recovery 
The mean extraction recovery of ISC from human plasma was determined by analyzing four 
replicates at the LLOQ, low-, medium-, high-QC, and ULOQ level.  The ISC peak area response 
of extracted QC samples was compared to that of the equivalent concentration level of the analyte 
directly spiked into the mobile phase and not subjected to extraction, which represents 100% 
recovery.  The extraction recovery of ISC from plasma was expressed as a percentage of the 
response of ISC diluted in mobile phase.  Since the extraction procedure resulted in an analyte 
concentration of 4 times (250-µL plasma samples are extracted, evaporated to dryness and then 
reconstituted with 62.5 µL of mobile phase), a concentration factor of 4 had to be applied to the 
ratio of the peak area response, as described previously (Loregian et al., 2006). 
 
2.5.2 Specificity and selectivity 
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Ten different batches of human plasma were evaluated as blank and spiked with ISC at LLOQ 
level to check for possible interferences from endogenous plasma components.  Chromatograms of 
blank samples were overlapped with those of LLOQ QC samples to verify the lack of analytic 
interference at the retention time of ISC.  Potential interferences due to concomitantly 
administrated drugs were  also investigated by analyzing both samples from several patients and 
chromatograms obtained by injecting the drugs listed in Table 1 and diluted in the mobile phase (at 
10 µg/mL). 
 
2.5.3 Precision and accuracy 
The ISC concentration was back-calculated from all calibrator points of the calibration curves and 
accuracy and precision of these measurements were determined.  Five replicates of each QC 
sample spiked with five different concentrations of ISC, corresponding to the LLOQ, low-, 
medium-, high-QC, and ULOQ were also analyzed to determine intra-day precision and accuracy.  
Inter-day values were obtained by duplicate analyses of the QC samples repeated on 5 different 
days.  Precision was calculated as the percentage of the coefficient of variation (CV) of the 
measured values, whereas the accuracy represents the percentage of deviation between nominal 
and measured concentration (% bias).  The acceptance criteria for all precision and accuracy 
parameters were deviations within 15% at each QC level, except for the LLOQ, where could not 
exceed by more than 20%, as requested by FDA guidelines (US Food and Drug Administration, 
2013).  
 
2.6.  Effect of dilution and carry-over effect 
The effect of dilution of plasma samples was validated with a ULOQ diluted to half, and analyzed 
five times.  Carry-over effect was tested by injecting three blank plasmas after the ULOQ: 
percentage of disappearance of analyte was evaluated. 
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2.7.  Stability evaluation 
ISC stability in human plasma was assessed by analyzing six replicates of QC samples at the low-, 
medium-, high-QC concentrations.  Three series were immediately analyzed, whereas the three 
other series were subjected to different conditions of storage/treatment that clinical samples can 
experience during TDM analysis.  The ISC peak area of both samples groups was then compared.  
The spiked plasma samples were exposed to the following different conditions: (a) storage at –
80°C for 5 months; (b) storage at RT for 48 h in the dark; (c) storage at RT for 48 h under ambient 
light (d) after three freeze-thaw cycles; and (e) after the thermization process (60°C for 60 min).  
Additionally, post-preparative sample stability of dried extracts (i.e., after SPE) at –20°C for 168 h 
and of extracts reconstituted in the mobile phase and incubated in the autosampler at 4°C for 96 h 
were analyzed.  The stability of both stock and working ISC solutions in methanol stored at −20°C 
was also investigated.   
 
2.8.  Statistics 
Statistical analysis was performed by the GraphPad Prism 6 (GraphPad Software Inc.) and 
Microsoft Excel.  In stability studies, comparisons of assay values were made by one-way analysis 
of variance (ANOVA).   
 
 
3.  RESULTS  
3.1  Sample preparation 
The purpose of sample extraction optimization was mainly to achieve high extraction recoveries 
and minimize interferences in order to improve the method sensitivity and the reliability of HPLC–
UV analysis.  Since ISC is highly bound (>99%) to human plasma proteins (Astellas Pharma US, 
2015), we first assessed protein precipitation methods using two different precipitating agents that 
are most commonly used (methanol and acetonitrile) at different dilution factors.  Protein plasma 
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precipitation with acetonitrile, when added at a ratio of 1:1, gave the best results (data not shown), 
achieving a high recovery of ISC (around 100%), but an unsatisfactory clean-up efficiency.  Other 
approaches were then tested such as liquid–liquid extraction using different solvents (i.e., 
chloroform, ethylacetate, ether, dichloromethane, and dichloroethane) and SPE using various 
cartridges (e.g., Oasis HLB, Oasis WAX, and Oasis MAX cartridges from Waters; Bond-Elut 
phenyl boronic acid and Bond-Elut C18 cartridges from Varian).  However, all these extraction 
approaches resulted in low clean-up efficiency and/or low recovery (data not shown).  In particular, 
a suboptimal recovery was in general observed in SPE, probably because the high extent of drug-
plasma proteins binding may have negatively affected the extraction recovery.  Therefore, we 
attempted the combination of the deproteinization using acetonitrile with a standard SPE protocol 
employing Waters Oasis HLB 1cc cartridges, as this strategy was previously found by our group to 
succeed in improving the extraction recovery of other drugs (e.g. simeprevir and daclatasvir) 
extensively bound to plasma proteins (Nannetti et al., 2016; Nannetti et al., 2017).  SPE was 
carried out following the protocol recommended by the producer, but the elution step was 
modified by decreasing the volume of the eluting solution (0.5 mL of methanol instead of 1 mL), 
as this allowed shortening the step of SPE eluates drying, while maintaining a high drug recovery.  
This combined protein precipitation-SPE procedure allowed to achieve a high and constant ISC 
recovery from human plasma at different drug levels (see Section 3.3.2), as well as to concentrate 
the samples in order to reach a high sensitivity, without having interferences at the retention time 
of the analyte (see Section 3.3.3).   
 
3.2  Optimization of chromatographic conditions 
The chromatographic conditions were optimized by testing different compositions of mobile 
phases and various chromatographic columns, including a Waters Atlantis dC18 (150 mm × 3.9 
mm,5 μm) column, a Symmetry C18 (75 mm × 4.6 mm, 3.5 μm) column, and an XTerra RP18 
(150 mm × 4.6 mm, 3.5 µm) column.  The best chromatographic separation was achieved using an 
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isocratic mixture of ammonium acetate buffer (pH 8.0, 10 mM) and acetonitrile (45:55, v/v) at a 
constant flow rate of 1.0 ml/min on an XTerra RP18 (150 mm × 4.6 mm, 3.5 μm; Waters) column.  
These conditions allowed the elution of ISC at a retention time of 8.7 min with a good resolution 
from plasma endogenous interferences, as shown in Figure 1.  The run time was 12 min, a time 
sufficient to remove all plasma components from the column.  Since adsorption of some azoles 
(e.g., posaconazole and itraconazole) to glassware was previously observed by us and others 
(Verweij-van Wissen et al., 2012 and unpublished data), the possible adsorption of ISC to 
glassware was investigated by using Waters silanized glass vials along with untreated glass vials 
for the reconstituted samples in the autosampler.  However, no difference was observed in ISC 
levels when using either type of vial (data not shown).  The UV detection was set at 285 nm, 
wherein ISC has the maximal absorbance (Figure 2) and the highest signal-to-noise ratio was 
recorded in chromatograms.  The detection at such wavelength allowed reaching a high sensitivity 
(see Section 3.3.1) resulting in a LLOQ two-fold lower than that reported by a UPLC-UV method 
that performed ISC detection at 260 nm (Verweij-van Wissen et al., 2012), wherein ISC 
absorbance is approximately half of that at 285 nm (Figure 2).  Figure 1 reports typical 
chromatograms obtained from (A) blank (drug-free) plasma; (B) blank plasma spiked with ISC at 
LLOQ (0.025 µg/ml), and (C) blank plasma spiked with ISC at ULOQ (10 µg/ml). 
 
3.3  Method validation 
The proposed analytical method was validated according to the FDA guidelines in terms of 
linearity, sensitivity, recovery, selectivity, specificity, precision, and accuracy (US Food and Drug 
Administration, 2013). 
 
3.3.1.  Linearity and sensitivity 
A nine-point calibration standard curve of ISC in plasma, ranging from 0.025 to 10 μg/mL, was 
prepared in triplicate in five independent runs.  This calibration curve covers the whole range of 
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ISC concentrations that have been so far observed in human plasma from clinical patients 
(Maertens et al., 2016).  The method was linear over the tested concentration range with 
correlation coefficients (r2) greater than 0.998 for each calibration curve.  The LOD, defined as the 
drug concentration that produces a signal-to-noise ratio (S/N) of 3, was 0.012 µg/mL.  The LLOQ 
was found to be 0.025 µg/mL, with an S/N of 6.3.  A representative chromatogram of this 
calibration point is shown in Figure 1B.  The lowest Ctrough values measured in patients at steady-
state (Maertens et al., 2016) are well within the concentration range of the calibration curve and 
considerably higher than the LLOQ.  These data confirmed the suitability of this method for 
routine TDM analysis of ISC in the clinical setting, suggesting the assay potential for dosing ISC 
even in patients with reduced compliance and in the case of low ISC concentrations due to drug-
drug interactions.     
 
3.3.2.  Extraction recovery 
The absolute recovery of ISC from human plasma ranged from 93.1% to 97.5% in the tested 
concentration range (0.025-10 µg/mL), with CV values varying from 2.4% to 4.9%.  Thus, 
differently from a previous extraction method for ISC from human plasma that reported a trend 
toward lower recovery at lower ISC concentrations (Jørgensen et al., 2017), our extraction 
procedure provides a constant recovery across the whole concentration range, also when using 
different lots of SPE cartridges.  Taken together, these data demonstrate that the sample 
preparation step is an efficient procedure, which concurs to the reliability and precision of this 
method.   
 
3.3.3.  Selectivity and specificity 
Analyses of ten different batches of commercial control human plasma were carried out to assess 
the selectivity and specificity of the method.  A representative chromatogram of drug-free plasma, 
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reported in Figure 1A, shows that no interfering peaks from endogenous plasma substances are 
detected within the retention time window of ISC (see also Figure S1 of Supporting Information).  
Method specificity was also evaluated by checking possible interferences at the analyte 
retention time after direct injection of 10 µg/mL of several other drugs (listed in Table 1 along 
with their retention time) diluted in the HPLC mobile phase.  None of the tested drugs interfered 
with ISC detection.  In addition, no analytical interference was observed during routine TDM 
analysis of clinical plasma samples from patients co-treated with ISC and other drugs.  The lack of 
analytic interference was also confirmed by the use of the peak purity checking system and the 
library matching of the Empower software. 
 
3.3.4.  Precision and accuracy 
Method precision (expressed as % CV) and accuracy (expressed as % bias) were evaluated in 
plasmas spiked with ISC at 5 concentrations (see also Section 2.5.3) as well as from the back-
calculated concentrations of ISC calibration standards; the results are reported in Table 2 and 
Table S1 of Supporting Information, respectively.  The intra-day and inter-day CVs were always 
equal or lower than 6.3% and 7.9%, respectively, in the tested concentration range.  The intra-day 
and inter-day deviations (% bias) of the means of the measured concentrations from their nominal 
concentrations ranged from -5.0% to 3.8% and from – 4.0% to 8.0%, respectively.  Overall, all 
accuracy and precision parameters were well within the acceptance criteria (<15%) set by FDA 
guidelines for method validation (US Food and Drug Administration, 2013), thus demonstrating 
that this method is highly reliable and reproducible for the determination of ISC levels in human 
plasma samples. 
 
3.4.  Effect of dilution and carry-over effect  
 14 
Quantification of half diluted ULOQ gave reliable results: 4.2% for bias and 4.9% for CV.  No 
carry-over effect was detected, since after injection of the ULOQ no ISC was quantifiable in three 
following plasma blanks. 
 
3.5  Participation in an external quality control (proficiency testing) program 
To further assess the precision and reliability of the method, we participated in an international 
proficiency testing program (“round robin test”).  Four single-blind QC samples of plasma 
containing ISC at unknown concentrations were prepared and distributed by Basilea 
Pharmaceutica Ltd. (Basel, Switzerland) to thirty analytical laboratories across Europe for an 
external quality assessment.  For each QC, the percentage of deviation (% bias) between the 
measured ISC level and the nominal concentration was calculated by Basilea Pharmaceutica.  
Feedback of the results was then given to the participants to enable them to improve their method 
when necessary.  The accuracy of our method ranged from 1.3% to 4.2% for all QC samples, thus 
well within the 15% of deviation requested by the FDA guidelines. 
 
3.6  Stability data 
Stock and working solutions of ISC dissolved in methanol were proved to be stable at -20°C for at 
least 6 months (reduction of ISC peak areas below than 15%), in accordance with data already 
published (Verweij-van Wissen et al., 2012; Fatiguso et al., 2017).  The stability of ISC was also 
investigated in plasma samples spiked with the drug at three different concentration levels and 
subjected to different storage and treatment conditions which clinical samples can commonly 
experience during the whole TDM process.  The ISC peak areas measured in treated QC samples 
were compared with those of immediately analyzed QCs at the respective concentration.  Each QC 
sample of both groups was assayed in triplicate.  ISC was considered stable when the deviation of 
ISC peak areas between these two groups was within 15%, as indicated in the FDA guidelines for 
bioanalytical methods validation (US Food and Drug Administration, 2013).  As summarized in 
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Table 3, ISC was found to be stable in human plasma under all tested stability conditions (one-way 
analysis of variance, not significant).  Specifically, stability was confirmed for ISC in plasma 
samples stored at RT for 48 h and after three freeze-thaw cycles, as reported in previous studies 
(Farowski et al., 2010; Toussaint et al., 2017; Jørgensen et al., 2017; Müller et al., 2017; Fatiguso 
et al., 2017; Verweij-van Wissen et al., 2012).  Stability of the analyte was also found in plasma 
stored at –80°C for 5 months, and when heated at 60°C for 60 min (Table 3), a safety procedure 
which is recommended to inactivate pathogenic microorganisms, including Aspergillus spp. fungi, 
in biological samples (US Environmental Protection Agency, 1979) and which we usually apply to 
all plasma samples received by our TDM unit (Loregian et al., 2006: Loregian et al., 2007).  Since 
we recently experienced the photochemical degradation of some drugs in plasma under daylight 
condition (Nannetti et al., 2017) and to the best of our knowledge, no detailed investigation on ISC 
photo-stability in human plasma under common light conditions that clinical samples can 
experience has been published, we also investigated the stability of ISC in plasma samples stored 
at RT for 48 h following exposure to ambient light (bench top).  No significant difference in ISC 
levels between plasma samples stored at RT for 48 h either in the dark or under ambient light was 
observed (Table 3).  Finally, the post-preparative stability of ISC both in dried and in reconstituted 
extracts was evaluated.  Table 3 shows that ISC was stable in dried and reconstituted extracts at -
20°C for at least 1 week and in autosampler at 4°C for 96 h, respectively. 
 
3.7  Analysis of patients samples 
The applicability of the method in the clinical setting was evaluated by analyzing plasma samples 
obtained from 10 patients treated with ISC.  The measured ISC plasma level ranged from 1.33 
µg/mL to 4.22 µg/mL (median of 2.38 µg/mL), which were within the range reported in the 
literature (Maertens et al., 2016).  Figure 3 shows two representative chromatograms of plasma 
samples of patients at steady-state receiving the recommended maintenance oral dose of 200 mg 
daily of ISC.  No potentially interfering peaks at the retention time of ISC were observed in all 
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analyzed clinical samples, thus confirming the clinical applicability of the present analytical 
method.  This assay is currently employed successfully for the routine TDM of ISC in our 
diagnostic Unit.  
 
4.  DISCUSSION AND CONCLUSIONS 
The present paper describes the development and validation of a simple, accurate, selective, and 
sensitive HPLC assay with UV detection for the quantification of ISC in human plasma.  Waiting 
to define the precise role of TDM for ISC, the determination of drug exposure is already required 
in selected clinical cases to adjust the drug dosage, in order to guarantee the effectiveness of 
therapy and to minimize the toxicity (Stott and Hope, 2017).  Previously published methods for the 
determination of ISC levels in plasma involved the use of UPLC, LC-MS/MS, or fluorescence 
detectors, which are not always available in analytical laboratories (Schmitt-Hoffmann et al., 2006 
a; Schmitt-Hoffmann et al., 2006 b; Farowski et al., 2010; Verweij-van Wissen et al., 2012; 
Toussaint et al., 2017; Müller et al., 2017; Fatiguso et al., 2017; McShane and Wang 2017).  To 
the best of our knowledge, this is the first HPLC method with UV detection developed for the 
determination of ISC in patients plasma, which uses commonly available equipment and still 
offers a sensitivity two or eight times higher (0.025 µg/mL versus 0.05 µg/mL and 0.2 µg/mL, 
respectively) than that of two previously published chromatographic methods not coupled with 
mass spectrometry detection (Verweij-van Wissen et al., 2012; Jørgensen et al., 2017).  The 
sensitivity of this method is also comparable or even higher (0.025 µg/mL versus 0.031 µg/mL - 
0.2 µg/mL) than that of some LC-MS/MS methods developed for TDM of ISC (e.g., Toussaint et 
al., 2017; Fatiguso et al., 2017; McShane and Wang 2017).  This method also exhibits great 
robustness and reproducibility, having intra-day and inter-day bias and CV values comparable to 
or better than those of other published methods (e.g., Toussaint et al., 2017; Fatiguso et al., 2017).  
In addition, another major advantage of this assay is that it employs an isocratic elution, since 
gradient elution requires control by a gradient HPLC pump system, re-equilibration time, perfect 
solvent mixing, etc.  Although this can imply a longer sample run than gradient-based methods, 
the run time of this assay is similar (12 minutes versus 6 - 13 minutes) to that reported from others 
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(e.g., Farowski et al., 2010; Verweij-van Wissen et al., 2012, Jørgensen et al., 2017; Fatiguso et 
al., 2017).  Nevertheless, the introduction of a gradient with an increasing acetonitrile 
concentration could speed up the ISC elution and reduce the run time.  Furthermore, taking into 
account the high precision and reproducibility of this assay along with the constant recovery of the 
extraction procedure, an internal standard was not required and hence not used in order to further 
simplify the method.  This method was fully validated according to the FDA recommendations and 
exhibited very good performance in an international quality assessment program involving thirty 
analytical laboratories across Europe.   
Stability studies of ISC under different common conditions to which the drug can be 
subjected during the TDM process showed that ISC concentration remains stable both in plasma 
and in processed samples under all tested conditions, including in plasma samples exposed to 
ambient light, a condition in which, to our knowledge, stability studies have not been previously 
published.  In addition, for the first time we investigated the stability of ISC to a thermal microbial 
inactivation at 60°C for 60 min, a safety procedure which is recommended to inactivate pathogenic 
microorganisms in biological samples.  Indeed, Fatiguso et al. recently reported the investigation 
of ISC stability at 58°C for 35 min, which corresponds to inactivation conditions for HIV samples 
(Fatiguso et al., 2017); however, more aggressive procedures have been recommended to 
inactivate pathogenic fungi, including Aspergillus spp. (US Environmental Protection Agency, 
1979).  Thus, the results of our studies of drug stability upon thermal inactivation could be most 
useful for properly handling ISC-containing plasma samples during routine clinical analyses of 
infected plasma samples from patients with invasive aspergillosis, wherein the fungus is present in 
the blood. 
Finally, the clinical applicability of the method and the appropriateness of the validated 
concentration range have been demonstrated in the analysis of plasma samples of patients 
receiving ISC. 
 18 
Overall, our method provides a simple, sensitive, precise, and reproducible assay for routine 
therapeutic drug monitoring of ISC and can be most useful in conventional hospital laboratories 
with standard equipment, as well as suitable for pharmacokinetic investigations. 
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FIGURES 
 
FIGURE 1 Typical chromatograms of (A) blank plasma sample, (B) plasma sample spiked with 
ISC at 0.025 µg/mL (LLOQ), and (C) plasma sample spiked with ISC at 10 µg/mL (ULOQ).  
LLOQ exhibited an S/N of 6.3. 
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FIGURE 2 The UV spectrum of ISC. 
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FIGURE 3 Chromatograms of plasma samples from patients treated with ISC in combination with 
(A) omeprazole, bisoprolol, lorazepam, cyclosporine A, prednisone, trimethoprim, and 
sulfamethoxazol; or (B) acyclovir, omeprazole, and prednisone.  The measured concentration of 
ISC was 1.81 µg/mL in sample (A) and 2.51 µg/mL in sample (B). 
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TABLE 1 
List of potentially co-administrated drugs tested for specificity with their relative retention time. 
_________________________________________________________________________________________________________ 
 
Drug name RT (min) Drug name RT (min) Drug name RT (min) 
abacavir 1.9 ganciclovir 1.6 simeprevir N.D. 
acyclovir 1.7 gentamicin 2.9 sofosbuvir 2.6 
ampicillin 1.3. ibuprofen N.D.  sofosbuvir metabolite GS-331007 1.6 
amprenavir 4.3 imipenem 1.4 Stavudine N.D. 
atazanavir 6.9 indinavir N.D. streptomycin N.D. 
bisoprolol N.D. kanamycin N.D. sulfamethoxazole N.D. 
carbenicillin 1.3 lamivudine 1.6 teicoplanin 1.6 
chloramphenicol 2.4 linezolid 2.1 tenofovir N.D. 
cyclosporine A N.D. lopinavir 4.0 tetracycline 1.8 
daclatasvir 3.6 lorazepam N.D. tigecycline 2.4 
daptomycin 1.4 paracetamol N.D. trimethoprim N.D. 
didanosine 1.6 posaconazole 7.1 vancomycin N.D. 
efavirenz 11.3 prednisone N.D. voriconazole 3.3 
erythromycin N.D. ribavirin N.D. Zalcitabine 1.6 
fluconazole N.D. rifampicin 2.4 Zidovudine 1.7 
foscarnet N.D. ritonavir N.D.   
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
N.D. = Not detected 
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TABLE 2 
Intra-day and inter-day accuracy and precision results in QC plasma samples. 
_________________________________________________________________________________________________________ 
Nominal concentration 
(µg/mL) 
Intra-day (n = 5) Inter-day (n = 5) 
 
                                                                                                                 ______________________________________________________________________________________________         _________________________________________________________________________________________________ 
 
 Mean measured 
concentration  
(µg/mL) 
Accuracya 
(% bias) 
Precision 
(% CV) 
Mean measured 
concentration  
(µg/mL) 
Accuracya 
(% bias) 
Precision 
(% CV) 
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
      0.025 (LLOQ) 0.024 -4.0 6.3 0.027 8.0 7.9 
      0.1 (low QC) 0.095 -5.0 5.2 0.096 -4.0 5.8 
      1.0 (medium QC) 0.994 -0.6 1.9 1.063 6.3 5.0 
      7.5 (high QC) 7.785 3.8 3.8 7.696 2.6 4.1 
      10.0 (ULOQ) 10.147 1.5 4.8 10.394 3.9 5.1 
____________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________ 
 
aAccuracy = [(measured concentration – nominal concentration)/nominal concentration] x 100 
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TABLE 3 
ISC stability in plasma samples and in dried or reconstituted extracts under different treatment/storage 
conditions. 
 
                                                                                                                              Nominal concentration (µg/mL) 
 0.1 1.0 7.5 
(A) In plasma incubated at 60°C for 60 min    
Deviation (%) 3.9 2.8 -3.5 
CV (%) 5.7 3.3 3.0 
(B) In plasma stored at room temperature for 48 h in the dark    
Deviation (%) -4.3 -3.3 -1.8 
CV (%) 5.0 2.1 3.0 
(C) In plasma stored at room temperature for 48 h exposed to daylight    
Deviation (%) -10.2 -8.8 -5.8 
CV (%) 6.9 6.3 5.5 
(D) In plasma stored at – 80°C for five months 
 
   
Deviation (%) 3.7 -5.4 -3.5 
CV (%) 4.2 2.8 4.4 
(E) In plasma after three freeze/thaw cycles    
Deviation (%) 5.9 6.5 -0.7 
CV (%) 5.5 4.8 2.0 
(F) In reconstituted extracts stored at 4°C for 96 h    
Deviation (%) 5.3 -1.6 4.0 
CV (%) 5.7 2.5 5.3 
(G) In dried extracts stored at – 20°C for 1 week    
Deviation (%) -2.9 -2.4 -0.6 
CV (%) 1.8 2.9 2.8 
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Supplementary Table S1 
 
Accuracy and precision results of back-calculated calibration standards 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aAccuracy = [(measured concentration – nominal concentration)/nominal concentration] x 100 
 
 
Nominal concentration 
(µg/mL) 
Mean measured 
concentration 
(µg/mL) 
Accuracya 
(% bias) 
Precision 
(% CV) 
0.025 0.026 4.0 7.6 
0.05 0.047 -6.0 5.7 
0.1 0.105 5.0 5.8 
0.2 0.207 3.5 3.9 
0.5 0.484 -3.2 2.1 
1.0 0.973 -2.7 3.2 
2.0 2.058 2.9 2.5 
5.0 5.071 1.4 2.2 
10.0 10.138 1.4 4.0 
